<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>abemaciclib resistance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/abemaciclib-resistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:27:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>abemaciclib resistance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>PROTACs Outperform MDM2 Inhibition in ER+ Cells</title>
		<link>https://bioengineer.org/protacs-outperform-mdm2-inhibition-in-er-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 02 Jun 2025 17:14:37 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[abemaciclib resistance]]></category>
		<category><![CDATA[ER+ breast cancer treatment]]></category>
		<category><![CDATA[MDM2 inhibition]]></category>
		<category><![CDATA[p53 mutation effects]]></category>
		<category><![CDATA[PROTACs in cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/protacs-outperform-mdm2-inhibition-in-er-cells/</guid>

					<description><![CDATA[In a groundbreaking study published in BMC Cancer, researchers have unveiled the remarkable efficacy of targeting the oncogenic regulator mdm2 through PROteolysis TArgeting Chimeras (PROTACs) in various breast cancer cell lines, including those resistant to abemaciclib and harboring both wildtype and mutated forms of p53. This innovative therapeutic strategy represents a significant leap forward in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">247943</post-id>	</item>
	</channel>
</rss>
